• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
What You Need To Know Ahead Of Abbott's Earnigns
 

What You Need To Know Ahead Of Abbott's Earnigns

on

  • 1,077 views

Abbott Labs (NYSE: ABT) is a staple in dividend investors portfolios thanks to a notable track record of dividend increases. The company continues to evolve following the spin-out of AbbVie, including ...

Abbott Labs (NYSE: ABT) is a staple in dividend investors portfolios thanks to a notable track record of dividend increases. The company continues to evolve following the spin-out of AbbVie, including the sale of slow growing generics to Mylan. However, Abbott is facing challenges and second quarter earnings may give investors insight into whether headwinds tied to Abbott's Similac recall last year are abating. In the following slideshow, you'll learn more about Abbott and key considerations to keep in mind when the company reports its second quarter earnings on July 16th.

Statistics

Views

Total Views
1,077
Views on SlideShare
491
Embed Views
586

Actions

Likes
1
Downloads
0
Comments
0

7 Embeds 586

http://www.fool.com 561
https://cms.fool.com 14
http://www.barchart.com 4
http://mockup.www.fool.com 3
http://m.fool.com 2
http://www.slideee.com 1
http://www.google.com 1
More...

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    What You Need To Know Ahead Of Abbott's Earnigns What You Need To Know Ahead Of Abbott's Earnigns Presentation Transcript

    • What You Need To Know Ahead of Abbott’s Earnings
    • Abbott Labs • Driving Abbott’s success: • Adult nutrition sales. • Diagnostic products. • Future growth opportunity: • Emerging markets.
    • Driving Abbott’s revenue First, let’s consider Abbott’s revenue sources. Abbott operates 4 segments: 1. Established pharmaceutical (generics). • $1.1 billion in Q1 sales. 2. Nutritional products (pediatric & adult). • $1.6 billion in Q1 revenue. 3. Diagnostic products (systems & testing). • $1.1 billion in Q1 sales. 4. Vascular devices/products (stents & other products). • $1.3 billion in Q1 revenue.
    • Driving Abbott’s revenue 1. Established pharmaceutical. 1. Ex-currency year-over-year sales down 0.7% 2. Including currency, YoY sales down 6.6%. 2. Nutritional products (pediatric & adult). • Ex-currency YoY sales down 1.7%. • Including currency, YoY sales down 4%. • Headwinds from 2013 recall remain, but should lessen. • Pediatric sales fell 8% in Q1. • Adult sales up 5.2%, ex-currency.
    • Driving Abbott’s revenue 1. Diagnostic products (systems & testing). • Ex-currency YoY sales up 5.1%. • Including currency, YoY sales up 2.6%. • Core lab products used for immunoassays up 11% YoY in U.S. 2. Vascular devices/products (stents & other products). • Ex-currency YoY sales up 0.3%. • Including currency, YoY sales down 1.2%.
    • Earnings outlook Abbott has beat analyst earnings forecasts in all four of the past four quarters, including by 13.9% in Q1. Estimates for this quarter are unchanged over the past 90 days at $0.51; however, analysts have reduced full year estimates by a penny to $2.19. •Revisions will be coming following its deal with Mylan. •Abbott retains its emerging market generic business. •A new entity that includes Abbott’s developed country business will be formed.
    • Earnings outlook •Analysts expect long-term earnings growth will lift EPS to $3.08 in 2017. •Following the Mylan deal, Abbott expects a 2% benefit to net income growth; however, off a lower base. •Deal reduces Abbott’s 2015 EPS by an estimated $0.22.
    • Fool-worthy thoughts •Nutrition headwinds should ease over time. •Adult nutrition demand should increase alongside demographics. •Diagnostic demand should climb due to aging boomers and ACA enrollment. •Device demand will remain challenging/highly competitive. •Opportunity for growth in ophthalmology. •Deal with Mylan removes slow growth developed market business. •Impact on EPS early, but faster growth rates thereafter. •Emerging market generic business offers faster growth as those economies strengthen.
    • Six stock picks poised for incredible growthSix stock picks poised for incredible growthSix stock picks poised for incredible growth Crush non-dividend paying counterparts over the long term with our FREE report on top dividend stocks.